News

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) featured several scientific abstracts during the 16th World Conference on Lung Cancer (WCLC) press program. Below are links to the releases for each individual abstract.

DENVER, Colo. — Previously, researchers reporting on SQUIRE study results demonstrated that the addition of necitumamub to gemcitabine-cisplatin improved overall survival in patients with stage IV squamous non-small cell lung cancer (NSCLC). Following up on these findings, Dr. Fred R. Hirsch, Professor of Medicine and Pathology at the University of Colorado, today presented additional analysis of the relationship with epidermal growth factor receptor (EGFR) protein and EGFR gene copy number at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC) in Denver, Colo.

DENVER, Colo. —Analysis of a large Phase III trial (S0819) investigating the addition of amonoclonal antibody targeting the epidermal growth factor receptor (EGFR) to chemotherapy in patients with non-small cell lung cancer (NSCLC) suggests that squamous cell lung cancer patients with tumors positive for the EGFR gene copy number (FISH) have a survival benefit, while non-squamous histology patients and those EGFR FISH-negative derive no survival advantage, according to research presented today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC) in Denver.

DENVER, Colo. – EGFR mutant (M+) is one of the most common driver oncogenes in lung cancer, typified by high response rates when treated with a tyrosine kinase inhibitor (TKI), and median progression free survival of 10 months, commonly due to emergence of T790M. The genomic architecture and spectra of EGFR M+ tumors may provide insights to mechanisms of treatment failure and no previous study describes this well.

DENVER, Colo. — Smoking cessation among patients enrolled in a low-dose computed tomography screening program is associated with a three-to-five times reduction in mortality, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC) in Denver.

DENVER, Colo. – Adding the monoclonal antibody bevacizumab to chemotherapy treatment for patients with surgically removed non-small cell lung cancer did not improve overall survival, according to research presented today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC) in Denver.

Pages